We examine effects of government spending on postdoctoral researchers' (postdocs) productivity in biomedical sciences, the largest population of postdocs in the US. We analyze changes in the productivity of postdocs before and after the US government's 1997 decision to increase NIH funding. In the first round of analysis, we find that more government spending has resulted in longer postdoc careers. We see no significant changes in researchers' productivity in terms of publication and conference presentations. However, when the population is segmented by citizenship, we find that the effects are heterogeneous; US citizens stay longer in postdoc positions with no change in publications and, in contrast, international permanent residents (green card holders) produce more conference papers and publications without significant changes in postdoc duration. Possible explanations and policy implications of the analysis are discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416806 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0124928 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Healthcare Financing in Saudi Arabia: A Comprehensive Review.
Healthcare (Basel)
December 2024
Department of Health Informatics, College of Applied Medical Sciences, Qassim University, P.O. Box 6666, Buraidah 41542, Saudi Arabia.
Saudi Vision 2030 is a game-changer for all aspects of the economy, including healthcare. This article provides a comprehensive overview of healthcare financing in the Kingdom of Saudi Arabia (KSA). It identifies key healthcare financing challenges that must be addressed to achieve the initiative's envisioned health system goals.
View Article and Find Full Text PDFElectronic Health Record Time Allocation Among Primary Care Clinicians at the Veterans Health Administration Using Virtual Observations.
J Gen Intern Med
January 2025
VA Puget Sound Health Care System, Seattle, WA, USA.
Background: Prior research has shown that primary care clinicians (PCPs) spend a large portion of clinic visits on tasks within the electronic health record (EHR). However, no time allocation studies have been done in the Veterans Health Administration (VHA) and little is known about EHR time spent during virtual visits.
Objective: To estimate the proportion of clinician time spent working within the EHR during primary care visits at VHA clinics.
Use of Clinical Trial Characteristics to Estimate Costs of New Drug Development.
JAMA Netw Open
January 2025
RAND, Santa Monica, California.
Article Synopsis
- Estimates indicate significant variation in R&D costs, with 20 large firms comprising 80.8% of patient-months and showing lower costs per patient-month compared to smaller firms.
- A novel methodology was used to analyze R&D costs per drug, focusing on discrete units of activity related to clinical trials and using data from 268 US publicly traded drug developers.
- The study found that R&D costs per new drug averaged around $1.31 billion, with a lower median cost of $708 million, highlighting a skewed distribution of expenses related to drug development.
Examples from US Policies to Reduce Oversupply and Overutilization: Lessons for the Japanese Health Care System.
Inquiry
January 2025
Health Analysis Division, Congressional Budget Office, U.S. Congress, USA.
The Japanese health care system provides universal coverage with relatively low cost sharing and patients have a free choice of providers. Although Japan's government price controls have helped to restrain the growth in health care spending, the country's rapidly growing elderly population and adoption of new drugs and technologies have placed increased fiscal pressures on its health care system. Additionally, the Japanese health care system does not have the infrastructure in place to restrain utilization, which may be a key driver of increases in health care spending.
View Article and Find Full Text PDFCost-Effectiveness of Breast Cancer Screening Using Digital Mammography in Canada.
JAMA Netw Open
January 2025
Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada.
Importance: Evolving breast cancer treatments have led to improved outcomes but carry a substantial financial burden. The association of treatment costs with the cost-effectiveness of screening mammography is unknown.
Objective: To determine the cost-effectiveness of population-based breast cancer screening in the context of current treatment standards.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!